MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Second-line chemotherapy represents an option in gastric cancer, especially for patients with
adequate performance status. Two randomized phase III trials comparing 2nd-line docetaxel
with best-supportive care have reported a benefit in favor of chemotherapy. Capecitabine is a
fluoropyrimidine carbamate, which has a broader spectrum of antitumor activity than other
fluoropyrimidines. In gastric cancer xenografts. metronomic capecitabine inhibited
angiogenesis, growth of gastric cancer and improved survival with less toxicity. Given its
potential low toxicity, the combination of docetaxel and metronomic capecitabine needs to be
evaluated to assess efficacy and tolerability in patients with advanced gastric cancer
previously treated with a fluoropyrimidine-based and platinum-based chemotherapy.